Sanstar approves ₹198 crore Ingredion stake in 2026

What shareholders approved at the June 20 EGM

Sanstar Limited shareholders have approved a preferential issue of equity shares to Corn Products Development Inc., an Ingredion group company. The resolution was passed at the company’s Extra-Ordinary General Meeting (EGM) held on June 20, 2026 through video conferencing and other audio-visual means (VC/OAVM). The allotment involves 1,80,24,157 equity shares to the non-promoter investor at an issue price of ₹110 per share. The fundraising aggregates to about ₹198.27 crore and is expected to result in the investor owning roughly 9% of Sanstar’s post-issue share capital. Sanstar also stated that the investment will not change its management or control.

Preferential issue terms: price, size, and premium

The company has disclosed the issue price at ₹110 per equity share, including a premium of ₹108. The total issue size has been cited at approximately ₹198 crore, with specific references to ₹198.3 crore and ₹198.27 crore across disclosures. Sanstar also indicated it expects gross proceeds of ₹198.27 crore (₹1,982,657,270). The allotment is being made on a preferential basis to a non-promoter category investor, consistent with the company’s stated structure. In-principle approvals for the preferential issue were received from BSE and NSE, as per the company’s announcement under Regulation 30 of the SEBI (LODR) framework.

Use of proceeds: working capital and corporate purposes

Sanstar said the proceeds will be used primarily for working capital requirements and general corporate purposes. Mr. Sambhav Gautam Chowdhary, Joint Managing Director, informed members about this planned utilisation. The company also indicated that deployment is expected in FY 2026-27. Separately, the disclosures referenced growth-linked requirements, including general corporate purposes connected to capacity expansion, without providing a detailed project-wise breakup. Acuité Ratings & Research Limited has been appointed as the monitoring agency for the preferential issue proceeds.

Governance rights granted to Ingredion’s subsidiary

Alongside approving the share issuance, shareholders sanctioned special rights for Corn Products Development Inc. in line with Regulation 31B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These rights include the ability to nominate a non-executive, non-independent director to Sanstar’s board (an “Investor Director”). The investor also secured pre-emptive rights to subscribe to additional equity shares in future issuances. In addition, Sanstar disclosed consultation rights, affirmative voting rights, and information rights on specified matters. The company noted these rights are part of the agreed governance framework while reiterating that management control remains unchanged.

EGM logistics: voting cut-off and meeting format

The EGM was held on June 20, 2026 at 11:00 a.m. IST through VC/OAVM. Sanstar also republished a newspaper advertisement about the EGM and the proposed preferential issue. The company stated that shareholders recorded as members or beneficial owners as on the cut-off date of June 15, 2026 were entitled to vote. According to a summary in the provided information, shareholders unanimously approved all five resolutions put to vote at the EGM.

Regulatory and procedural steps still pending

While shareholder approval is in place, Sanstar still needs to meet regulatory conditions connected to completion of the allotment. The company disclosed requirements that include filing a listing application within 20 days of allotment. It also referenced the need for statutory approvals from bodies including SEBI, RBI, and the Ministry of Corporate Affairs (MCA), as applicable. These steps will determine the final timeline for listing and credit of the preferential shares.

Related constitutional changes approved

Sanstar’s disclosures also referred to amendments linked to implementing the transaction documents and rights structure. Shareholders approved amendments to the Memorandum of Association (MOA) and Articles of Association (AOA) to align with the shareholder arrangements tied to the preferential issue. Separately, the board had approved an increase in authorised share capital from ₹38.00 crore to ₹50.00 crore, subject to shareholder approval. These changes are intended to support the capital raise and embed governance terms into the company’s framework.

Strategic context: joint venture and specialty ingredients push

The preferential investment is part of a wider strategic partnership between Sanstar and Ingredion. The partnership includes establishing a jointly owned venture in India focused on specialty pharmaceutical excipients and other specialty ingredient products. Disclosures referenced a JV entity named Spark Ingredients Private Limited, where Sanstar holds a 30% stake, along with Ingredion India Private Limited and Amishi Drugs and Chemicals Private Limited. The JV’s commercial operations target was stated as 30 to 36 months post-incorporation. Sanstar’s current installed capacity was cited at 2,350 TPD, up from 1,100 TPD.

Market snapshot: issue price versus traded price

Sanstar’s share price was stated as ₹116.45 as of June 20, 2026. Against that reference price, the preferential issue price of ₹110 per share implies a discount to the cited traded price on the day. At the same time, the company noted that the issue price includes a premium of ₹108, indicating the pricing is well above the face value of the equity share. The allotment size and governance package make the transaction noteworthy for investors tracking ownership changes and shareholder rights in listed mid-cap companies.

Key facts table

Why this matters for investors

For Sanstar, the approval locks in a sizeable equity inflow earmarked for working capital and general corporate purposes in FY 2026-27. For shareholders, the transaction is also about governance, because the investor’s board nomination, pre-emptive rights, and affirmative voting rights can influence how certain specified decisions are made even without a change in management control. The structure is explicitly positioned as a non-promoter allotment and has been presented as control-neutral by the company. The next milestones are execution steps, including completing statutory and exchange-related processes and meeting listing and filing timelines linked to the allotment.

What to watch next

Sanstar has indicated that completion remains subject to regulatory and statutory conditions and filings, including a listing application within 20 days of allotment. Investors will watch for the final allotment, credit of shares, and formal board changes following the Investor Director nomination right. Separately, progress updates on the jointly owned venture focused on specialty pharmaceutical excipients, including the stated 30 to 36 month commercial operations target, will be relevant for tracking how the broader partnership develops.